Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

1.3K
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
1.3K
Hemodialysis II: Procedure and Complications01:24

Hemodialysis II: Procedure and Complications

1.2K
DialyzersA hemodialysis (HD) dialyzer is a plastic cartridge containing thousands of parallel hollow fibers, which serve as semipermeable membranes. These fibers are typically made from cellulose-based or other synthetic materials. During HD, blood is pumped into the top of the cartridge and distributed among these fibers. Simultaneously, dialysis fluid, known as dialysate, is introduced into the bottom of the cartridge, bathing the outside of the fibers. Across the semipermeable membrane,...
1.2K
Drug Accumulation During Multiple Dosing: Intermittent IV Infusions01:24

Drug Accumulation During Multiple Dosing: Intermittent IV Infusions

312
Intermittent intravenous (IV) infusion is a method of drug administration where medications are delivered over short infusion periods followed by intervals of no drug delivery. This approach helps to prevent sustained high drug concentrations in the bloodstream, reducing the risk of adverse effects associated with prolonged exposure. Unlike continuous infusion, steady-state concentrations may not be achieved during a single dosing cycle but can be reached through repeated...
312
Local Anesthetics: Adverse Effects01:12

Local Anesthetics: Adverse Effects

892
While local anesthetics are generally safe and well-tolerated, they can occasionally cause adverse effects that vary in severity. Local anesthetics can induce toxicity at two distinct levels. They can either produce local effects through direct contact with the neural elements or be absorbed into the bloodstream from the injection site, leading to systemic effects.
Once absorbed into the systemic circulation, local anesthetics can affect the organs that depend on the functioning of sodium...
892
Peritoneal Dialysis II: Peritoneal Dialysis Systems and Complications01:25

Peritoneal Dialysis II: Peritoneal Dialysis Systems and Complications

1.1K
Peritoneal dialysis (PD) is a medical process that removes waste products and excess fluid from the body using the peritoneal membrane as a natural filter.Peritoneal Dialysis MethodsSeveral methods can be used for peritoneal dialysis, including Acute Intermittent Peritoneal Dialysis, Continuous Ambulatory Peritoneal Dialysis, and Automated Peritoneal Dialysis, also known as Continuous Cyclic Peritoneal Dialysis.Acute Intermittent Peritoneal Dialysis (AIPD) is used for patients with uremic...
1.1K
Drug toxicity: Drug–Drug Interaction01:30

Drug toxicity: Drug–Drug Interaction

108
Drug–drug interactions can precipitate toxicity through multiple mechanisms. Absorption interactions alter how drugs enter the body, exemplified when ranitidine increases the absorption of basic drugs, while cholestyramine decreases the levels of propranolol. Protein binding interactions occur when drugs share the same binding sites on plasma proteins. Drugs like aspirin and warfarin, when bound in excess, can lead to increased free drug concentrations, enhancing the potential for...
108

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Identifying and predicting fast versus slow Parkinson's disease motor progressors using clinical and digital data.

BMJ neurology open·2026
Same author

Confidence-guided outlier refinement and collaborative embedding for unsupervised person re-identification.

Scientific reports·2026
Same author

Genetically proxied GLP1R expression does not predict exenatide response in the Exenatide-PD3 trial.

Brain : a journal of neurology·2026
Same author

Clinical prognostic indicators in multiple system atrophy.

Brain : a journal of neurology·2026
Same author

Peripheral and CSF protein quantification in Parkinson's disease and multiple system atrophy-the nucleic acid-linked immuno-sandwich assay.

Brain communications·2026
Same author

Foxiangsan Modulates Dopaminergic and Motilin Pathways to Improve Gastrointestinal Motility in Diabetic Gastroparesis.

Neuroendocrinology·2026
Same journal

A novel GNAO1 variant associated with variable and mild phenotypes in a Spanish family.

Journal of movement disorders·2026
Same journal

Myoclonus and Gaze Palsy in Childhood-Onset SQSTM1-Related Neurodegeneration.

Journal of movement disorders·2026
Same journal

TBC1D2B-related Neurodevelopmental Disorder with Gingival Overgrowth and Movement Disorders: A Case Series and Literature Review.

Journal of movement disorders·2026
Same journal

Distinct and Combined Cognitive Profiles associated with Depression and Anxiety in Early Parkinson's Disease.

Journal of movement disorders·2026
Same journal

Improvement of Refractory Restless Legs Syndrome in a Parkinson's Disease Patient After Semaglutide Treatment: A Novel Clinical Observation.

Journal of movement disorders·2026
Same journal

Serum Neuronal Extracellular vesicles for RT-QuIC assay to detect Pathological α-Synuclein in Synucleinopathies.

Journal of movement disorders·2026
See all related articles

Related Experiment Video

Updated: Feb 26, 2026

Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease
06:45

Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease

Published on: October 4, 2021

3.6K

Liquid Levodopa/Carbidopa: Old Solution, Forgotten Complication

Nirosen Vijiaratnam1, Shuli Cheng1, Kelly Lucinda Bertram1,2

  • 1Department of Neurosciences, Alfred Hospital, Melbourne, Australia.

Journal of Movement Disorders
|July 15, 2017
PubMed
Summary

No abstract available in PubMed .

More Related Videos

Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease
05:51

Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease

Published on: October 14, 2021

4.5K
The 6-hydroxydopamine Rat Model of Parkinson's Disease
08:10

The 6-hydroxydopamine Rat Model of Parkinson's Disease

Published on: October 27, 2021

13.2K

Related Experiment Videos

Last Updated: Feb 26, 2026

Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease
06:45

Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease

Published on: October 4, 2021

3.6K
Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease
05:51

Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease

Published on: October 14, 2021

4.5K
The 6-hydroxydopamine Rat Model of Parkinson's Disease
08:10

The 6-hydroxydopamine Rat Model of Parkinson's Disease

Published on: October 27, 2021

13.2K